Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.45 |
| ▸ | HTR3A | P46098 | 2/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.44 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
| ▸ | METAP2 | P50579 | 1/20 | 0.40 |
| ▸ | METAP1 | P53582 | 1/20 | 0.40 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | XDH | P47989 | 1/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1691424 | 0.81 | HTR3A (0.45) | HRH3HTR3AKCNH2NOTUMMETAP2 | |
| SCHEMBL10537216 | 0.81 | AOC3 (0.50) | MEN1KMT2AHRH3HTR3AKCNH2 | |
| SCHEMBL5562512 | 0.80 | NOTUM (0.47) | HTR3ANOTUMMETAP2XDH | |
| SCHEMBL1373045 | 0.80 | KMT2A (0.51) | MEN1LMNAKMT2AHRH3HTR3A | |
| SCHEMBL497670 | 0.80 | GSK3B (0.52) | LMNAHRH3HTR3AKCNH2LRRK2 | |
| SCHEMBL2675558 | 0.79 | CDK5 (0.44) | HRH3HTR3AKCNH2METAP2 | |
| SCHEMBL31020318 | 0.76 | HTR3A (0.57) | MEN1LMNAKMT2AHRH3HTR3A | |
| SCHEMBL18339224 | 0.75 | MAPK1 (0.48) | KMT2ASMN1; SMN2KDM4EALDH1A1HPGD | |
| SCHEMBL1150386 | 0.74 | — | — | |
| SCHEMBL497977 | 0.74 | PDE4A (0.55) | MEN1LMNAKMT2ASMN1; SMN2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | APOLLO ADMINISTRATIVE AGENCY LLC, AS SUCCESSOR AGENT | 2017-07-20 | — | — | US | disclosed |
| US-9650378-B2 | (1-azinone)-substituted pyridoindoles | ALBANY MOLECULAR RESEARCH, INC. (US) | 2017-05-16 | — | — | US | disclosed |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | HARMONY BIOSCIENCES, LLC | 2016-06-09 | — | — | US | disclosed |
| US-20140206696-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | ALBANY MOLECULAR RESEARCH, INC. (US) | 2014-07-24 | — | — | US | disclosed |
| US-8278316-B2 | Aza pyridone analogs useful as melanin concentrating hormone receptor-1 antagonists | BRISTOL-MYERS SQUIBB COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20120010209-A1 | IMIDAZO[1,2-A]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS | MERCK SHARP & DOHME LLC | 2012-01-12 | — | — | US | disclosed |
| US-20110319439-A1 | AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY | 2011-12-29 | — | — | US | disclosed |
| EP-1697370-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2006-09-06 | — | — | EP | disclosed |
| WO-2005063761-A1 | AZABICYCLIC HETEROCYCLES AS CANNABINOID RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2005-07-14 | — | — | WO | disclosed |
| US-4810705-A | BENZODIAZEPINE DERIVATIVE ANTAGONISTS | SANOFI (FR) | 1989-03-07 | — | — | US | disclosed |
| EP-0156734-A2 | Triazolo[4,3-b]pyridazines, process for their preparation and pharmaceutical compositions containing them | SANOFI S.A. (FR) | 1985-10-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319439-A1 | AZA PYRIDONE ANALOGS USEFUL AS MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS | MCHR1, MCHR2, MC1R | MEN1 939/4885LMNA 4448/4885KMT2A 1331/4885 |
| US-20170204095-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | MEN1 1448/4885LMNA 1957/4885KMT2A 3915/4885 |
| US-20120010209-A1 | IMIDAZO[1,2-A]PYRIDINES AND IMIDAZO[1,2-b]PYRIDAZINES AS MARK INHIBITORS | MARK3, MARK4, MAP2 | MEN1 3814/4885LMNA 1904/4885KMT2A 498/4885 |
| US-20140206696-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | MEN1 1448/4885LMNA 1957/4885KMT2A 3915/4885 |
| US-20160159798-A1 | (1-AZINONE)-SUBSTITUTED PYRIDOINDOLES | NR3C2, NR2E3, NR0B1 | MEN1 1448/4885LMNA 1957/4885KMT2A 3915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.